{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002978","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.045620+00:00","generated_at":"2026-05-24T18:45:16.994733+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026","bullets":["Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.","Proceeds to advance Halneuron clinical development and for working capital.","Offering closed March 14, 2025; Maxim Group LLC acted as sole placement agent.","Company expects cash runway through Q1 2026; Halneuron Phase 2b CINP interim data planned for Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002978","json":"https://secwatch.observer/filing/0001558370-25-002978.json","markdown":"https://secwatch.observer/filing/0001558370-25-002978.md","text":"https://secwatch.observer/filing/0001558370-25-002978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025002978/0001558370-25-002978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025002978/dwtx-20250312x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:45:16.994733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}